The Data and Safety Monitoring Board questioned whether the data used in the trial was complete and called on AstraZeneca to update its information as quickly as possible.Source: Washington Post
0
0
Happy
0 %
Sad
0 %
Excited
0 %
Sleppy
0 %
Angry
0 %
Surprise
0 %
